Literature DB >> 6420163

Protein binding of enprofylline.

K Tegnér, O Borgå, I Svensson.   

Abstract

The protein binding of enprofylline, 3-propylxanthine, in plasma was studied by equilibrium dialysis and ultrafiltration under various experimental conditions. A limited comparison with theophylline was also undertaken. The mean fraction of enprofylline bound in human plasma at 20 degrees C was 47.3 +/- 1.1% (SD), which was only 2% less than theophylline. The binding of the two drugs increased dramatically in the pH range 7.2 to 7.8, as reported previously for theophylline. Reasonable agreement was found between equilibrium dialysis and ultrafiltration, but the latter technique proved impractical, because pH control was difficult to achieve. A pronounced species difference in the binding of enprofylline was found. At pH 7.4 an almost constant level of binding of 57% in dog and 81% in rat was found up to 2.10(-5) M (approx. 4 mg/l). Corresponding values in human and monkey plasma were 47 and 48%, respectively, up to 10(-4) M (approx. 20 mg/l).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6420163     DOI: 10.1007/bf00542362

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Protein binding of salicylate in uremic and normal plasma.

Authors:  O Borgå; I O Cederlöf; V A Ringberger; A Norlin
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  The plasma protein binding of amphetamine, catecholamines and related compounds.

Authors:  G Franksson; E Anggård
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1970

3.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

4.  Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals.

Authors:  M Brinkschulte; U Breyer-Pfaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

5.  Binding of xanthine derivatives to human serum albumin as a function of pH.

Authors:  A A Albary; J J Vallner; C W Whitworth
Journal:  Acta Pharm Suec       Date:  1981

6.  Enprofylline, a principally new antiasthmatic xanthine.

Authors:  C G Persson; G Kjellin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-10

7.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Enprofylline kinetics in healthy subjects after single doses.

Authors:  O Borgå; K E Andersson; L E Edholm; P O Fagerström; E Lunell; C G Persson
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

9.  Tracheal relaxant and cardiostimulant actions of xanthines can be differentiated from diuretic and CNS-stimulant effects. Role of adenosine antagonism?

Authors:  C G Persson; I Erjefält; L E Edholm; J A Karlsson; C J Lamm
Journal:  Life Sci       Date:  1982-12-13       Impact factor: 5.037

10.  Seizure activity in animals given enprofylline and theophylline, two xanthines with partly different mechanisms of action.

Authors:  C G Persson; I Erjefält
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-08
View more
  3 in total

1.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

2.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Effects of probenecid on enprofylline kinetics in man.

Authors:  O Borgå; R Larsson; E Lunell
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.